BIOSECURE Act - Looking Ahead

In this episode of Choate’s Life Sciences Insights podcast series, Adam Bookbinder and Sara Frank discuss the current status of the BIOSECURE Act in Congress, and the related implications and practical takeaways life science companies may want to consider at this time. Currently stalled in Congress despite strong bipartisan support, the Act and its impending impact has been the source of considerable speculation over the past several months. If passed, the BIOSECURE Act will effectively ban U.S. life sciences companies from contracting with certain Chinese biotech companies to prevent the potential misuse of U.S. genomic data by the Chinese government and military.